Earnings Look Back: Exact Sciences Is Down 5.4% Since Reporting Quarterly Results 1 Week Ago (EXAS)
Comtex SmarTrend(R) - Mon May 12, 11:45AM CDT
When Exact Sciences (NASDAQ:EXAS) reported earnings a week ago on May 1st, 2014, analysts, on average, expected the company to report a loss of $0.19 on sales of $831.0 thousand. The company actually reported a loss of $0.23 per share on sales of $294.0 thousand, missing EPS estimates by $0.04 and missing revenue estimates by $0.5 million. Since the company's report, shares of Exact Sciences have fallen from $12.56 to $11.88, representing a loss of 5.4% in the past 11 days.
2014 FDA Drug Approval Calendar
at The Street - Mon May 12, 8:22AM CDT
A list of drugs under FDA review and scheduled FDA advisory panel meetings.
Technical Data on Biotech Stocks -- Research on Exact Sciences, Amgen, Exelixis, and Incyte
PR Newswire - Tue May 06, 8:57AM CDT
On Monday, May 05, 2014, the NASDAQ Composite ended at 4,138.06, up 0.34%, the Dow Jones Industrial Average finished the day 0.11% higher at 16,530.55, and the S&P 500 closed at 1,884.66, up 0.19%. The gains were broad based as eight out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 672.57, up 0.56%, and the index has advanced 0.12% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corporation (NASDAQ: EXAS), Amgen Inc (NASDAQ: AMGN), Exelixis Inc. (NASDAQ: EXEL) and Incyte Corp. Ltd (NASDAQ: INCY). Free technical research on EXAS, AMGN, EXEL and INCY can be downloaded upon signing up at:
Released and Scheduled Earnings Results - Analyst Notes on Pacira, Exact Sciences, Synageva, Agios and Vanda Pharmaceuticals
PR Newswire - Tue May 06, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Exact Sciences Corporation (NASDAQ: EXAS), Synageva BioPharma Corp. (NASDAQ: GEVA), Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2054-100free.
Exact Sciences to Participate in May Investor Conferences
Business Wire - Mon May 05, 7:02AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will participate in two investor conferences during May.
Why EXACT Sciences Corporation Shares Briefly Tumbled
Sean Williams, The Motley Fool - Motley Fool - Thu May 01, 3:32PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of EXACT Sciences , a molecular diagnostics...
Why You Should Watch Merrimack, Exact Sciences, and Incyte Today
George Budwell, The Motley Fool - Motley Fool - Thu May 01, 8:10AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Exact Sciences , Incyte Corporation and Merrimack Pharmaceuticals . Exact Sciences misses on earnings and revenue Exact Sciences posted a wider loss...
Exact Sciences Reports First-Quarter 2014 Financial Results
Business Wire - Thu May 01, 6:31AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial results for the quarter March 31, 2014.
Exact Sciences to Host First-Quarter 2014 Results Webcast and Call
Business Wire - Fri Apr 25, 8:00AM CDT
Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company will host a webcast and conference call to discuss its first-quarter 2014 financial results on May 1, 2014.
Exact Sciences Falls 3.86% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Mon Apr 14, 6:02PM CDT
Exact Sciences (NASDAQ:EXAS) traded in a range yesterday that spanned from a low of $11.51 to a high of $12.76. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $12.25 on volume of 2.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Exact Sciences Announces Successful Completion of Public Offering of Common Stock
Business Wire - Wed Apr 09, 3:05PM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced underwritten public offering of its common stock at a price of $12.75 per share to the public.
Stocks Review on Top Gainers -- Research on Genco Shipping & Trading, Exact Sciences, Baltic Trading, and Eagle Bulk Shipping
PR Newswire - Mon Apr 07, 11:38AM CDT
The US markets saw a negative sentiment on Friday, April 4, 2014, with the NASDAQ Composite closing at 4,127.73, down 2.60%, the Dow Jones Industrial Average ending the session at 16,412.71, down 0.96%, and the S&P 500 declining 1.25% to finish the trading session at 1,865.09. The session witnessed selling pressure in the Information Technology, Consumer Discretionary, Health Care, and Materials sectors that negatively impacted the broader market. A number of stocks saw large movements, including Genco Shipping & Trading Ltd (NYSE: GNK), Exact Sciences Corp. (NASDAQ: EXAS), Baltic Trading Ltd (NYSE: BALT) and Eagle Bulk Shipping Inc. (NASDAQ: EGLE). Free technical research on GNK, EXAS, BALT and EGLE can be downloaded upon signing up at:
Nasdaq stocks posting largest percentage increases
AP - Fri Apr 04, 5:20PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Why Exact Sciences (EXAS) Stock Is Higher On Friday
at The Street - Fri Apr 04, 8:56AM CDT
Shares of Exact Sciences (EXAS) are up 5.30% to $13.60 after the molecular diagnostics company announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price of $12.75 per share to the public.
Exact Sciences Prices Public Offering of Common Stock
Business Wire - Fri Apr 04, 7:42AM CDT
Exact Sciences Corp. (NASDAQ: EXAS) today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a price of $12.75 per share to the public. The net proceeds to Exact from this offering are expected to be approximately $119.7 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Exact. The offering is expected to close on or about April 9, 2014, subject to the satisfaction of customary closing conditions. Exact has granted the underwriters a 30-day option to purchase up to an aggregate of 1,500,000 additional shares of common stock. Exact anticipates using the net proceeds from the offering to fund its efforts to obtain FDA approval of its Cologuard test, to fund Cologuard commercialization activities, to fund product development efforts, and for general corporate and working capital purposes.
Exact Sciences (EXAS) Jumps: Stock Adds 10.2% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:51AM CDT
Exact Sciences Corporation was a big mover last session, as its shares rose over 10% on the day.
Why Exact Sciences, Builders FirstSource, and Clayton Williams Energy Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:00PM CDT
Over the weekend, investors who tuned into 60 Minutes got a look at the new Michael Lewis book on high-frequency trading, with dire conclusions about how traders take advantage of both institutional and individual investors. Yet even with that...
Today's Dead Cat Bounce Stock Is Exact Sciences Corporation (EXAS)
at The Street - Mon Mar 31, 8:45AM CDT
Trade-Ideas LLC identified Exact Sciences Corporation (EXAS) as a "dead cat bounce" (down big yesterday but up big today) candidate
CBS Outdoor Americas Climbs on First Day of Trading; FDA Advisory Panel Recommends Approval of Exact Sciences Corporation's Cologuard
ACCESSWIRE - Sun Mar 30, 11:16PM CDT
CBS Outdoor Americas Inc. (NYSE: CBSO) - For an in-depth report on CBS Outdoor Americas Inc. follow: www.BullTrends.com/stockquote/CBSO
'Mad Money' Lightning Round: Sell Starbucks at $72
at The Street - Sat Mar 29, 5:00AM CDT
Cramer prefers Boeing over AerCap Holdings and CBS Outdoor over Chambers Street Properties.